Table.3 The distributions of APOE genotypes and alleles in patients with AF and control groups
From: Association between the APOE gene polymorphism and lipid profile and the risk of atrial fibrillation
|  | AF patients (n = 706) | Controls (n = 661) | χ2 | P |
|---|---|---|---|---|
Genotype | n = 706 | n = 661 |  |  |
E2/E2 | 4(0.57) | 5(0.76) | 5.32 | 0.379 |
E2/E3 | 96(13.60) | 98(14.83) | ||
E2/E4 | 13(1.84) | 14(2.12) | ||
E3/E3 | 380(53.82) | 378(57.19) | ||
E3/E4 | 199(28.19) | 151(22.84) | ||
E4/E4 | 14(1.98) | 15(2.27) | ||
Allele | n = 1412 | n = 1322 |  |  |
ε2 | 117(8.29) | 122(9.23) | 3.01 | 0.222 |
ε3 | 1055(74.72) | 1005(76.02) | ||
ε4 | 240(16.99) | 195(14.75) | ||
Hardy-Weinberg equilibrium | χ2  = 8.05, P = 0.090 | χ2  = 1.38, P = 0.849 |  |  |